Healthcare >> Analyst Interviews >> August 5, 2013

New Product Generation and an Easing Regulatory Environment in Biopharmaceuticals

Baum, Andrew
Andrew Baum, M.D., is the Global Head of Healthcare Research for Citi Research. Before joining Citi in 2011, Dr. Baum covered European Pharmaceuticals at Morgan Stanley for 14 years. Previous to that he was a U.K. Pharmaceuticals and Biotechnology analyst at Salomon Brothers. From 1994 to 1996, Dr. Baum was a practicing physician at the Royal National Orthopaedic Radcliffe Hospital in Oxford (the medical centre of Oxford University) where he completed his residency. Dr. Baum was the top ranked European Pharmaceutical Analyst in the Extel Poll six times. His team consistently ranked in the top three teams in external EU and global investor polls (Institutional Investor, Greenwich and Reuters). Dr. Baum holds an M.A. degree in Physiological Sciences and an M.D. degree from Oxford University. Dr. Baum is a member of the American Heart Association, American Society of Oncology and the DIA. He is also a Fellow of the Royal Society of Medicine. Profile
TWST: Looking back, the Big Pharma group has done pretty well relative to the market so far this year. Why?

Dr. Baum: Well, it's a combination of factors. I think the bulk of the